Lifeline Biotechnologies Announces Start of China Market Introduction of Proprietary MastaScope Diagnostic Product Following Granting of Chinese SDA Registration Number Sep 8, 2005 1:58:00 PM Copyright Business Wire 2005 RENO, Nev.--(BUSINESS WIRE)--Sept. 8, 2005--
Lifeline Biotechnologies, Inc. (PINK:LBTN) today announced that the company has been granted a registration number by the Chinese SDA, for the company's MastaScope(TM) product. This SDA registration number is comparable to the CE mark and FDA 510K approvals that have already been granted for the product. The SDA registration enables the company to begin market introduction of the MastaScope in China.
Jim Holmes, chairman of Lifeline Technologies, made the announcement adding: "We have been working diligently for almost a year now on obtaining approval and are delighted that we are now able to commence our marketing effort in this country in earnest." Holmes noted that according to the Surveillance and Risk Assessment Division, CCDP, Health Canada, the incidence of breast cancer among Chinese women was 32 women per 100,000 population in 1993. "That was 12 years ago and other reports, such as that found in a People's Daily Online report from March of 2002, have indicated that the incidence of breast cancer among Chinese women was rising at a rate of at least 27 percent over the past decade with some 40 percent of Chinese women diagnosed with breast cancer dying within five years because the cancer is already advanced at the time of diagnosis. We believe as the MastaScope can help in the early detection and diagnosis of cancer and other abnormalities of the breast."
As a result of being granted the Chinese SDA, Lifeline reports that a significant meeting among prominent Chinese and Japanese physicians and surgeons to demonstrate and train them in the attributes and use of the MastaScope in the early detection of breast cancer is scheduled for later this month. "This demonstration and training session will be held at one of Beijing's major hospitals and we believe it will be attended by physicians representing eight to 10 Chinese and Japanese hospitals," Holmes said.
Last September Lifeline announced that it entered into a four-year contract with International Medical Consulting Group (IMCG) of Dallas, Texas, for its Chinese company, Shanghai Science Medical Equipment, Ltd. to distribute Lifeline's proprietary MastaScope Mammary Ductoscopy System in the People's Republic of China.
Lifeline Biotechnologies, Inc. is a company with innovative medical technologies committed to the improvement of the quality of life through exceptional health care systems. These technologies focus on prevention, early detection, diagnosis and quick recovery of a number of disease conditions. The company's Cancer Detection technologies deal with cutting edge innovation to assist practicing physicians in the delivery of quality medical care. The MastaScope(TM) is used in the early detection of cancer and other abnormalities of the breast. The MastaScope(TM) has completed development and has entered the marketplace in the US and internationally. The First Warning System(TM) for assisting in the early detection of breast cancer and the OvaScope(TM) for assisting in the early detection of ovarian cancer are continuing to be developed by the company. More information is available at the company's website: www.lbti.com.
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. In particular, when used in the preceding discussion, the words, "believe", "expects", "projects", "forecasts", "intends", "will", "anticipated", "could", or "may", and similar conditional expressions are intended to identify forward-looking statements within the meaning of the act and are subject to the safe harbor created by the act. Except for historical information, all of the statements, expectations and assumptions contained in the foregoing are forward-looking statements that involve a number of risks and uncertainties.
Source: Lifeline Biotechnologies, Inc.
---------------------------------------------- Martin E. Janis & Company Inc. Bev Jedynak 312-943-1100 ext. 12 bjedynak@janispr.com
Lifeline Biotechnologies Announces New Study from Professor Kefah Mokbel That Will Test Company's First Warning System and MastaScope Products Together for Assistance in the Detection of Breast Cancer Aug 11, 2005 1:35:00 PM Copyright Business Wire 2005 RENO, Nev.--(BUSINESS WIRE)--Aug. 11, 2005--
Lifeline Biotechnologies, Inc. (OTC:LBTN) today announced that Professor Kefah Mokbel, consultant breast surgeon at St. George's Hospital and Medical School and Professor at Brunel Institute of Cancer Genetics & Pharmacogenomics and his research team in the UK have commenced a new study, examining the role of mammary ductoscopy, using MastaScope, in conjunction with dynamic thermal analysis, using the First Warning System and proteomics in the early detection of breast cancer.
This study has been approved by the Ethics' Committee at St. George's Hospital Medical School in London. Participants include patients with suspected breast cancer, patients with benign breast disease, healthy volunteers and women who are known to harbor breast cancer causing genes (BRCA-1 or BRCA-2). Professor Mokbel believes that these novel strategies for breast cancer detection will complement screening mammography, which is regarded as the gold standard screening tool. Furthermore, mammary ductoscopy, using the MastaScope, may complement the role of dynamic thermal analysis in cases where these tests are positive, but anatomical imaging is negative for malignancy. This potential application may help resolve the issue of false-positive results, associated with screening tools based on physiological and biological principles. Researchers hope that if the preliminary results of this study are successful that they can be presented in the fifth European Breast Cancer Conference in France early next year.
Lifeline Biotechnologies has been in the process developing the First Warning System for a number of years and already markets the MastaScope. "We look forward to the results of Professor Mokbel's study, as this is a major step in the commercialization and introduction to the market of our First Warning System," said Jim Holmes, chairman of Lifeline.
Lifeline Biotechnologies, Inc. is a company with innovative medical technologies committed to the improvement of the quality of life through exceptional health care systems. These technologies focus on prevention, early detection, diagnosis and quick recovery of a number of disease conditions. The company's Cancer Detection technologies deal with cutting edge innovation to assist practicing physicians in the delivery of quality medical care. The MastaScope(TM) is used in the early detection of cancer and other abnormalities of the breast. The MastaScope(TM) has completed development and has entered the marketplace in the US and internationally. The First Warning System(TM) for assisting in the early detection of breast cancer and the OvaScope(TM) for assisting in the early detection of ovarian cancer are continuing to be developed by the company. More information is available at the company's website: www.lbti.com.
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. In particular, when used in the preceding discussion, the words, "believe," "expects," "projects," "forecasts," "intends," "will," "anticipated," "could," or "may," and similar conditional expressions are intended to identify forward-looking statements within the meaning of the act and are subject to the safe harbor created by the act. Except for historical information, all of the statements, expectations and assumptions contained in the foregoing are forward-looking statements that involve a number of risks and uncertainties.
Source: Lifeline Biotechnologies, Inc.
---------------------------------------------- Martin E. Janis & Company Inc. Bev Jedynak 312-943-1100 Ext. 12 bjedynak@janispr.com
Lifeline Biotechnologies Announces Completion of Independent Audit for Fiscal 2003 and 2002 Jul 18, 2005 8:00:00 AM Copyright Business Wire 2005 RENO, Nev.--(BUSINESS WIRE)--July 18, 2005--
Lifeline Biotechnologies, Inc. (OTC:LBTN) today announced that the audited financial statements for fiscal 2003 and 2002 will be posted to the company's website and available for downloading. These statements, audited by Lopez, Blevins, Bork & Associates, LLP of Houston, Texas, reflect the company's financial condition at December 31, 2003 and 2002. Now that the 2003 and 2002 audit has been completed the 2004 audit is expected to be commenced within the next few weeks.
Jim Holmes, Acting CEO and Chairman of Lifeline, said: "This audit marks the beginning of a new era for Lifeline. Upon the completion of the 2004 audit we expect to file the appropriate filing with the SEC to become a reporting company." Holmes declined to state specifically when the 2004 audit will be available but noted that with the systems in place that have resulted in the 2003 and 2002 audits completion, "we do not anticipate any problems or the long delays previously experienced."
Holmes said that as expected, the company's audit contains "going concern" language. "As a company that is developing medical products that require regulatory approvals and market acceptance, there are losses that are incurred and the need to continually raise money during this phase of development. We strongly believe the research dollars and staff time we've incurred developing our First Warning System (FWS) and other product lines can result in life-saving benefits to women in the future."
Dr. Bill Reeves, developer of Lifeline's FWS, added, "I believe that we have taken a big step in the future growth of Lifeline. This audit is the first block in the building of a solid foundation to move forward."
In other matters, Holmes announced that Frank Clark, former Lifeline CEO, resigned his position due to health reasons. "Unfortunately Frank's health does not permit him to take the active role he had planned in Lifeline's business development. However, we are hopeful that his expertise can be provided to us as he is able in an informal consultant role."
Holmes also said that Jonathan Reeves, Lifeline's president, has resigned from the company to pursue other interests. "Jonathan provided strong support to Lifeline during the past years and we wish him continued success in his ventures." Holmes stated that the company will make an announcement in the near future as to future management.
Lifeline Biotechnologies, Inc. is a company with innovative medical technologies committed to the improvement of the quality of life through exceptional health care systems. These technologies focus on prevention, early detection, diagnosis and quick recovery of a number of disease conditions. The company's Cancer Detection technologies deal with cutting edge innovation to assist practicing physicians in the delivery of quality medical care. The MastaScope(TM) is used in the early detection of cancer and other abnormalities of the breast. The MastaScope(TM) has completed development and has entered the marketplace in the US and internationally. The First Warning System(TM) for assisting in the early detection of breast cancer and the OvaScope(TM) for assisting in the early detection of ovarian cancer are continuing to be developed by the company. More information is available at the company's website: www.lbti.com.
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. In particular, when used in the preceding discussion, the words, "believe", "expects", "projects", "forecasts", "intends", "will", "anticipated", "could", or "may", and similar conditional expressions are intended to identify forward-looking statements within the meaning of the act and are subject to the safe harbor created by the act. Except for historical information, all of the statements, expectations and assumptions contained in the foregoing are forward-looking statements that involve a number of risks and uncertainties.
Source: Lifeline Biotechnologies, Inc.
---------------------------------------------- Martin E. Janis & Company Inc. Bev Jedynak 312-943-1100 ext. 12 bjedynak@janispr.com
Lifeline's MastaScope Featured In Full Page Article in Clinical Lab Products Magazine Jul 11, 2005 11:04:00 AM Copyright Business Wire 2005 RENO, Nev.--(BUSINESS WIRE)--July 11, 2005--
Lifeline Biotechnologies, Inc. (OTC:LBTN) today announced that Louis Keith, MD, PhD, Lifeline's scientific director, was interviewed for a full page article on the company's activities in breast cancer screening and specifically its MastaScope(TM). The article appears in the June 2005 issue of Clinical Lab Products, which is the leading product news magazine for key decision-makers in the clinical diagnostic laboratory, reaching more than 45,000 key individuals. The article can be accessed at the magazine's website: www.clpmag.com/.
The article, by Nicholas Borgert, focuses on the ability of the company's MastaScope product to help detect breast cancer at its earliest stages.
Lifeline Biotechnologies, Inc. is a company with innovative medical technologies committed to the improvement of the quality of life through exceptional health care systems. These technologies focus on prevention, early detection, diagnosis and quick recovery of a number of disease conditions. The company's Cancer Detection technologies deal with cutting edge innovation to assist practicing physicians in the delivery of quality medical care. The MastaScope(TM) is used in the early detection of cancer and other abnormalities of the breast. The MastaScope(TM) has completed development and has entered the marketplace in the US and internationally. The First Warning System(TM) for assisting in the early detection of breast cancer and the OvaScope(TM) for assisting in the early detection of ovarian cancer are continuing to be developed by the company. More information is available at the company's website: www.lbti.com.
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. In particular, when used in the preceding discussion, the words, "believe", "expects", "projects", "forecasts", "intends", "will", "anticipated", "could", or "may", and similar conditional expressions are intended to identify forward-looking statements within the meaning of the act and are subject to the safe harbor created by the act. Except for historical information, all of the statements, expectations and assumptions contained in the foregoing are forward-looking statements that involve a number of risks and uncertainties.
Source: Lifeline Biotechnologies, Inc.
---------------------------------------------- Martin E. Janis & Company Inc. Bev Jedynak 312-943-1100 ext. 12 bjedynak@janispr.com
-------------------- Choosing individual stocks without any idea of what you're looking for (or without reliable information) is like running through a dynamite factory with a burning match. You may live, but your still an idiot. Posts: 5320 | From: Syracuse, NY | Registered: Apr 2005
| IP: Logged |
posted
watch this for the next week.... at .0048 now
-------------------- Choosing individual stocks without any idea of what you're looking for (or without reliable information) is like running through a dynamite factory with a burning match. You may live, but your still an idiot. Posts: 5320 | From: Syracuse, NY | Registered: Apr 2005
| IP: Logged |
posted
Any hope in this reaching $1.50 a share after two R/S on this my intial shares have become just 550 shares bringing my average to $1.50 a share. I really dont for see this moving any were with out revenue , but i really dont want to sell at a lose right now , i recommend being carefull with this one.
Posts: 181 | From: Quebec | Registered: Aug 2005
| IP: Logged |
this co is worth more than 200k, dont hold for long like polar said, but she should come up, started a little push today
-------------------- Choosing individual stocks without any idea of what you're looking for (or without reliable information) is like running through a dynamite factory with a burning match. You may live, but your still an idiot. Posts: 5320 | From: Syracuse, NY | Registered: Apr 2005
| IP: Logged |
-------------------- Choosing individual stocks without any idea of what you're looking for (or without reliable information) is like running through a dynamite factory with a burning match. You may live, but your still an idiot. Posts: 5320 | From: Syracuse, NY | Registered: Apr 2005
| IP: Logged |
-------------------- Choosing individual stocks without any idea of what you're looking for (or without reliable information) is like running through a dynamite factory with a burning match. You may live, but your still an idiot. Posts: 5320 | From: Syracuse, NY | Registered: Apr 2005
| IP: Logged |
posted
Figures just when i get fustrated and sell the other day for a $850 loss it pops and starts riseing.
Posts: 181 | From: Quebec | Registered: Aug 2005
| IP: Logged |
posted
Lifeline Biotechnologies Successfully Completes Testing of MastaScope Diagnostic Product in China Friday October 28, 7:30 am ET
RENO, Nev.--(BUSINESS WIRE)--Oct. 28, 2005--Lifeline Biotechnologies, Inc. (Pink Sheets: LBTN - News) today announced that the Company has successfully completed the testing of MastaScope(TM) at three different hospitals in China. The MastaScope(TM) product provides sharp, clear, and accurate imagery of the intraductal breast tissues and abnormalities. ADVERTISEMENT
The MastaScope(TM) was tested on 17 patients by Chinese surgeons under the direction of Dr. Pedro Escobar. Dr. Escobar is a Fellow in Breast and Gynecologic Oncology at the Cleveland Clinic Foundation. The surgeons were able to insert the MastaScope(TM), which is a micro-endoscope, through the patient's nipple so the surgeon can examine the interior of the milk duct during the examination. Lifeline Biotechnologies already has been issued the Import Registration Number by the Chinese SDA, which is the equivalent to the American FDA.
"The MastaScope(TM) was very well received by chief breast surgeons at the Zheijang Province People's Hospital, as well as the China-Japan Friendship Hospital and Beijing Third University Hospital. All the scopes and duct excisions were successful," stated Dr. Pedro Escobar.
"The completion of the testing of the MastaScope(TM) will enable us to continue with our strategy in entering the Chinese and Asian markets," stated Jim D. Holmes, CEO of Lifeline Biotechnologies, Inc.
About Lifeline Biotechnologies, Inc.
Lifeline Biotechnologies, Inc. is a company with innovative medical technologies committed to the improvement of the quality of life through exceptional health care systems. These technologies focus on prevention, early detection, diagnosis and quick recovery of a number of disease conditions. The company's Cancer Detection technologies deal with cutting edge innovation to assist practicing physicians in the delivery of quality medical care. The MastaScope(TM) is used in the early detection of cancer and other abnormalities of the breast. The MastaScope(TM) has completed development and has entered the marketplace in the US and internationally. The First Warning System(TM) for assisting in the early detection of breast cancer and the OvaScope(TM) for assisting in the early detection of ovarian cancer are continuing to be developed by the company. More information is available at the company's website: www.lbti.com.
Safe Harbor
This release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 27E of the Securities Act of 1934. Statements contained in this release that are not historical facts may be deemed to be forward-looking statements. Investors are cautioned that forward-looking statements are inherently uncertain. Actual performance and results may differ materially from that projected or suggested herein due to certain risks and uncertainties including, without limitation, ability to obtain financing and regulatory and shareholder approval for anticipated actions.
-------------------------------------------------------------------------------- Contact: Big Apple Consulting USA, Inc. for Lifeline Biotechnologies, Inc.: Matt Maguire, 407-884-0444 or 1-866-THE-APPLE
-------------------- Choosing individual stocks without any idea of what you're looking for (or without reliable information) is like running through a dynamite factory with a burning match. You may live, but your still an idiot. Posts: 5320 | From: Syracuse, NY | Registered: Apr 2005
| IP: Logged |
-------------------- Choosing individual stocks without any idea of what you're looking for (or without reliable information) is like running through a dynamite factory with a burning match. You may live, but your still an idiot. Posts: 5320 | From: Syracuse, NY | Registered: Apr 2005
| IP: Logged |
-------------------- Choosing individual stocks without any idea of what you're looking for (or without reliable information) is like running through a dynamite factory with a burning match. You may live, but your still an idiot. Posts: 5320 | From: Syracuse, NY | Registered: Apr 2005
| IP: Logged |
posted
With the Cleveland Clinic behind this and the fact that they have now completed some successful testing I think this will continue to rise
Posts: 88 | From: US | Registered: Sep 2005
| IP: Logged |
-------------------- Choosing individual stocks without any idea of what you're looking for (or without reliable information) is like running through a dynamite factory with a burning match. You may live, but your still an idiot. Posts: 5320 | From: Syracuse, NY | Registered: Apr 2005
| IP: Logged |
posted
its wayyyy overbought now, might go back to 27, i think we see a shake on monday, and another surge tues
-------------------- Choosing individual stocks without any idea of what you're looking for (or without reliable information) is like running through a dynamite factory with a burning match. You may live, but your still an idiot. Posts: 5320 | From: Syracuse, NY | Registered: Apr 2005
| IP: Logged |
posted
I think this keeps going. The news today is very positive and it keeps it going.I am grabbing some right here. We should go to .05 at least before any pull back. It moves to easy.
Posts: 494 | From: Martinez | Registered: Sep 2003
| IP: Logged |
posted
Ive been in since .009 a while back...im extremely pleased...i knew that a company with a real product and that has a definite client base would be profitable!!! Its only gonna keep doing good!!!
Posts: 575 | From: Lawrenceburg | Registered: Feb 2005
| IP: Logged |
posted
But why would you bu this POS, i intially bought in two years ago only to go through a R/S and end up with 550 shares , at an average of $1.50 a share ,Knowing that i would never see a PPS that high i sold the otherday at a loss of $850. What product are you talking about ,The Matascope thing thats been adround for 2 years and has done nothing, How much market is there for this , think about it. You could get a couple hundred sales from major hospitals ,across the global , but once they have one , it's not like they will need another one next month, year , these things probally are good for a decade. so your sales base is limted , plus the cost to buy one , not every hospital will buy one .
Posts: 181 | From: Quebec | Registered: Aug 2005
| IP: Logged |
posted
Lifeline Biotechnologies Unveils the MastaScope(TM) at the Fall Chinese National Medical Equipment Show Wednesday November 2, 8:00 am ET RENO, Nev.--(BUSINESS WIRE)--Nov. 2, 2005--Lifeline Biotechnologies, Inc. (Pink Sheets: LBTN - News) today announced that the company is unveiling the MastaScope(TM) at the Fall Chinese National Medical Equipment Show in Chongqin City, Sichuang province. Shanghai Science Medical Equipment Co, Ltd will be demonstrating the MastaScope(TM) and presenting Dr. Escobar's product demonstration at the show that runs from October 31st through November 10th. The National Medical Equipment Show caters to over 3000 medical equipment manufacturers in addition to many influential representatives and doctors from all over the China. Shanghai Science Medical Equipment Co, Ltd has a strong distribution network, including numerous sub dealers and representatives who have expressed interest and will be seeing the product demonstration for the first time. "We are very excited about our presence at this show. It follows the successful completion of the product testing, and as a result we expect that it will propel our company to the next level. We expect the unveiling to be a huge success given the great exposure, timing, and ability to offer very competitive pricing on our MastaScope(TM)," stated Jim Holmes, CEO of Lifeline Biotechnologies, Inc. About Lifeline Biotechnologies, Inc. Lifeline Biotechnologies, Inc. is a company with innovative medical technologies committed to the improvement of the quality of life through exceptional health care systems. These technologies focus on prevention, early detection, diagnosis and quick recovery of a number of disease conditions. The company's Cancer Detection technologies deal with cutting edge innovation to assist practicing physicians in the delivery of quality medical care. The MastaScope(TM) is used in the early detection of cancer and other abnormalities of the breast. The MastaScope(TM) has completed development and has entered the marketplace in the US and internationally. The First Warning System(TM) for assisting in the early detection of breast cancer and the OvaScope(TM) for assisting in the early detection of ovarian cancer are continuing to be developed by the company. More information is available at the company's website: www.lbti.com. Safe Harbor This release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 27E of the Securities Act of 1934. Statements contained in this release that are not historical facts may be deemed to be forward-looking statements. Investors are cautioned that forward-looking statements are inherently uncertain. Actual performance and results may differ materially from that projected or suggested herein due to certain risks and uncertainties including, without limitation, ability to obtain financing and regulatory and shareholder approval for anticipated actions.
________________________________________ Contact: Big Apple Consulting USA, Inc. for Lifeline Biotechnologies, Inc. Matt Maguire, 407-884-0444 or 1-866-THE-APPLE
________________________________________ Source: Lifeline Biotechnologies, Inc.
Posts: 105 | From: "Western", NY USA | Registered: Aug 2004
| IP: Logged |
UBBFriend: Email this page to someone!
Printer-friendly view of this topic
